• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

News

CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer

19 de June de 2013
EMBO Mol Med. 2013 Jul;5(7):1067-86. doi: 10.1002/emmm.201202341.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-06-19 10:00:002013-06-19 10:00:00CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer

Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis

15 de June de 2013
Stem Cells. 2013 Sep;31(9):1954-65. doi: 10.1002/stem.1454.ABSTRACTReceptor…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-06-15 10:00:002013-06-15 10:00:00Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis

Evaluation of PAX3 genetic variants and nevus number

12 de June de 2013
Pigment Cell Melanoma Res. 2013 Sep;26(5):666-76. doi: 10.1111/pcmr.12130.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-06-12 10:00:002013-06-12 10:00:00Evaluation of PAX3 genetic variants and nevus number

Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells

8 de May de 2013
Int J Cancer. 2013 Nov 15;133(10):2464-72. doi: 10.1002/ijc.28259.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-05-08 10:00:002013-05-08 10:00:00Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells

Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells

8 de May de 2013
Int J Cancer. 2013 Nov 15;133(10):2464-72. doi: 10.1002/ijc.28259.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-05-08 10:00:002013-05-08 10:00:00Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells

Functional and structural analysis of C-terminal BRCA1 missense variants

25 de April de 2013
PLoS One. 2013 Apr 17;8(4):e61302. doi: 10.1371/journal.pone.0061302.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-04-25 10:00:002013-04-25 10:00:00Functional and structural analysis of C-terminal BRCA1 missense variants

Strongyloidiasis and infective dermatitis alter human T lymphotropic virus-1 clonality in vivo

18 de April de 2013
PLoS Pathog. 2013;9(4):e1003263. doi: 10.1371/journal.ppat.1003263.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-04-18 10:00:002013-04-18 10:00:00Strongyloidiasis and infective dermatitis alter human T lymphotropic virus-1 clonality in vivo

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk

2 de April de 2013
PLoS Genet. 2013;9(3):e1003212. doi: 10.1371/journal.pgen.1003212.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-04-02 10:00:002013-04-02 10:00:00Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk

Molecular characterization of HTLV-1 gp46 glycoprotein from health carriers and HAM/TSP infected individuals

21 de March de 2013
Virol J. 2013 Mar 6;10:75. doi: 10.1186/1743-422X-10-75.ABSTRACTBACKGROUND:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-03-21 10:00:002013-03-21 10:00:00Molecular characterization of HTLV-1 gp46 glycoprotein from health carriers and HAM/TSP infected individuals

The impact of KRAS mutations on VEGF-A production and tumour vascular network

20 de March de 2013
BMC Cancer. 2013 Mar 18;13:125. doi: 10.1186/1471-2407-13-125.ABSTRACTBACKGROUND:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-03-20 10:00:002013-03-20 10:00:00The impact of KRAS mutations on VEGF-A production and tumour vascular network

Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches

6 de March de 2013
Clin Cancer Res. 2013 Jun 1;19(11):2842-9. doi: 10.1158/1078-0432.CCR-12-3458.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-03-06 11:00:002013-03-06 11:00:00Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches

Serum 25-hydroxyvitamin D3 levels and vitamin D receptor variants in melanoma patients from the Mediterranean area of Barcelona

19 de February de 2013
BMC Med Genet. 2013 Feb 16;14:26. doi: 10.1186/1471-2350-14-26.ABSTRACTBACKGROUND:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-02-19 11:00:002013-02-19 11:00:00Serum 25-hydroxyvitamin D3 levels and vitamin D receptor variants in melanoma patients from the Mediterranean area of Barcelona
Page 75 of 88«‹7374757677›»

Filter by categories

  • Alemany’s & Piulats’s lab (135)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (112)
  • Sin categoría (12)
  • Sureda's & Farre's Lab (319)
  • Viñals's lab (113)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}